Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.57 |
| ▸ | MAG | P20916 | 6/20 | 0.50 |
| ▸ | SELL | P14151 | 2/20 | 0.50 |
| ▸ | SELP | P16109 | 2/20 | 0.50 |
| ▸ | SELE | P16581 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380203 | 0.96 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL12313946 | 0.96 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL29699102 | 0.94 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL30649952 | 0.94 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL31126371 | 0.94 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL30651291 | 0.94 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL30650374 | 0.94 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL22969674 | 0.94 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL20971391 | 0.94 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL30649466 | 0.94 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146254-A1 | Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications | SEGENA CORPORATION S.A. (UY) | 2026-05-28 | — | — | US | disclosed |
| US-12611419-B2 | Liposomal composition for use in a method of treating Parkinson's disease | INNOMEDICA HOLDING AG (CH) | 2026-04-28 | — | — | US | disclosed |
| EP-4622674-A1 | ENHANCING OLIGONUCLEOTIDE IMMUNOMODULATORY ACTIVITY THROUGH DIANOPHORE LONG-LASTING MODIFICATION: METHODS AND APPLICATIONS | SEGENA CORPORATION S.A. (UY) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025064617-A2 | LIPOSOMAL FORMULATIONS FOR TREATMENT OF GM1 DEFICIENCIES | SENEB BIOSCIENCES, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4335506-A2 | LIPOSOMES COMPRISING SPHINGOMYELIN | InnoMedica Holding AG (CH) | 2024-03-13 | — | — | EP | disclosed |
| EP-3727328-B1 | LIPOSOMES COMPRISING SPHINGOMYELIN | INNOMEDICA HOLDING AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-20230210875-A1 | LIPOSOMAL COMPOSITION FOR USE IN A METHOD OF TREATING PARKINSON'S DISEASE | INNOMEDICA HOLDING AG (CH) | 2023-07-06 | — | — | US | disclosed |
| US-11607385-B2 | Liposomes comprising sphingomyelin | INNOMEDICA HOLDING AG (CH) | 2023-03-21 | — | — | US | disclosed |
| US-20220226357-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | UNIV JEFFERSON (US) | 2022-07-21 | — | — | US | disclosed |
| CN-114761021-A | Methods for treating neurodegenerative disorders | 托马斯杰斐逊大学 | 2022-07-15 | — | — | CN | disclosed |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | KIMURA TEIJI | 2011-03-17 | — | — | US | disclosed |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| WO-2010098495-A1 | IMIDAZOLYLPYRAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010098487-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010098488-A1 | ARYL IMIDAZOLE COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2148673-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | Eisai R&D Management Co., Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2008139984-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | SIGLEC7 666/4885MAG 774/4885SELL 1093/4885 |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | APP, BACE1, PSEN1 | SIGLEC7 4393/4885MAG 2582/4885SELL 3935/4885 |
| US-12611419-B2 | Liposomal composition for use in a method of treating Parkinson's disease | SMPD2, SMPD1, SGMS2 | SIGLEC7 59/4885MAG 11/4885SELL 148/4885 |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | APP, PSEN1, BACE1 | SIGLEC7 4705/4885MAG 2721/4885SELL 4466/4885 |
| US-20230210875-A1 | LIPOSOMAL COMPOSITION FOR USE IN A METHOD OF TREATING PARKINSON'S DISEASE | GBA1, GALC, SMPD3 | SIGLEC7 88/4885MAG 32/4885SELL 1210/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | SIGLEC7 4334/4885MAG 1646/4885SELL 4005/4885 |
| US-20260146254-A1 | Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications | CD44, ADAR, TLR9 | SIGLEC7 15/4885MAG 2714/4885SELL 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.